Veracity Capital LLC Sells 328 Shares of Novo Nordisk A/S (NYSE:NVO)

Veracity Capital LLC lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 5.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,959 shares of the company’s stock after selling 328 shares during the quarter. Veracity Capital LLC’s holdings in Novo Nordisk A/S were worth $765,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Novo Nordisk A/S by 245.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 68,477 shares of the company’s stock valued at $6,227,000 after acquiring an additional 48,678 shares during the last quarter. Bank of Nova Scotia acquired a new position in Novo Nordisk A/S during the third quarter valued at approximately $263,000. Toronto Dominion Bank raised its position in shares of Novo Nordisk A/S by 93.3% in the third quarter. Toronto Dominion Bank now owns 45,912 shares of the company’s stock valued at $4,175,000 after purchasing an additional 22,165 shares during the period. Ancora Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 100.0% in the third quarter. Ancora Advisors LLC now owns 2,538 shares of the company’s stock worth $231,000 after buying an additional 1,269 shares during the last quarter. Finally, Advisors Asset Management Inc. boosted its holdings in shares of Novo Nordisk A/S by 142.9% during the 3rd quarter. Advisors Asset Management Inc. now owns 45,625 shares of the company’s stock worth $4,149,000 after buying an additional 26,843 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. Argus boosted their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, June 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday. Finally, The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 price target for the company. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average price target of $145.67.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO traded down $4.11 during trading on Thursday, hitting $138.87. 7,455,753 shares of the stock were exchanged, compared to its average volume of 3,491,449. The company has a market capitalization of $623.18 billion, a price-to-earnings ratio of 47.89, a price-to-earnings-growth ratio of 1.41 and a beta of 0.41. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $148.15. The company’s fifty day simple moving average is $135.95 and its 200-day simple moving average is $124.47.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. The firm had revenue of $9.52 billion for the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. Sell-side analysts expect that Novo Nordisk A/S will post 3.44 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.